Who are the main competitors of Nichi-Iko Pharmaceutical?

Overview of Nichi-Iko Pharmaceutical

Nichi-Iko Pharmaceutical, established in 1965, has matured into one of Japan’s largest generic drug manufacturers by sales. Over the decades, the company has built a reputation based on quality assurance and operational excellence. Its emphasis on premium-quality generic pharmaceuticals has driven the company to consistently achieve significant revenue milestones—for example, in FY2014 it became the first Japanese generic medicine manufacturer to reach JPY100 billion in annual sales, and by the fiscal year ended March 31, 2018, consolidated net sales reached JPY164.7 billion. This strong market performance is not only indicative of its domestic eminence but also reflects the company’s strategic direction toward fulfilling the global demand for generic and biosimilar treatments with a commitment to value-added products.

Market Position and Segments 
Nichi-Iko’s market position is characterized by a robust footprint in the domestic generic drug market and a clear strategic orientation toward expanding its presence internationally. With a highly diversified product portfolio, the company competes in multiple therapeutic areas such as cardiovascular, anti-infectives, and biosimilars. Elevated by substantial investments in quality control and

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.